MA31799B1 - Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p) - Google Patents

Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)

Info

Publication number
MA31799B1
MA31799B1 MA32805A MA32805A MA31799B1 MA 31799 B1 MA31799 B1 MA 31799B1 MA 32805 A MA32805 A MA 32805A MA 32805 A MA32805 A MA 32805A MA 31799 B1 MA31799 B1 MA 31799B1
Authority
MA
Morocco
Prior art keywords
modulators
compositions
sphingosin
phosphate receptor
sphingosine
Prior art date
Application number
MA32805A
Other languages
Arabic (ar)
English (en)
Inventor
Colleen Ruegger
Michael AMBÜHL
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31799(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31799B1 publication Critical patent/MA31799B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention concerne des compositions stables comprenant un modulateur du récepteur de sphingosine 1-phosphate (s1p), convenant pour une utilisation en tant que forme de dosage. Les modulateurs du récepteur s1p sont de manière typique des analogues de sphingosine, comme des dérivés de 2-amino-propane-1,3-diol ou de 2-aminopropanol substitué en position 2, par exemple un composé comprenant un groupe de la formule.
MA32805A 2007-10-12 2010-04-30 Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p) MA31799B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
PCT/US2008/079264 WO2009048993A2 (fr) 2007-10-12 2008-10-09 Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)

Publications (1)

Publication Number Publication Date
MA31799B1 true MA31799B1 (fr) 2010-10-01

Family

ID=40032615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32805A MA31799B1 (fr) 2007-10-12 2010-04-30 Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)

Country Status (32)

Country Link
US (6) US8673918B2 (fr)
EP (7) EP2465492B1 (fr)
JP (2) JP6034000B2 (fr)
KR (3) KR101600098B1 (fr)
CN (1) CN101820916A (fr)
AR (1) AR068986A1 (fr)
AU (1) AU2008310846C1 (fr)
BR (1) BRPI0818161B8 (fr)
CA (2) CA2925175A1 (fr)
CL (1) CL2008003003A1 (fr)
CO (1) CO6270342A2 (fr)
DK (1) DK2952177T3 (fr)
EC (1) ECSP10010169A (fr)
ES (2) ES2864671T3 (fr)
HR (1) HRP20150838T1 (fr)
HU (2) HUE053835T2 (fr)
IL (3) IL204514B (fr)
JO (2) JOP20080436B1 (fr)
MA (1) MA31799B1 (fr)
MX (1) MX337152B (fr)
MY (1) MY159358A (fr)
NZ (1) NZ600355A (fr)
PE (2) PE20130309A1 (fr)
PL (2) PL2465492T3 (fr)
PT (2) PT2465492E (fr)
RU (1) RU2010118457A (fr)
SG (2) SG187458A1 (fr)
SI (2) SI2952177T1 (fr)
TN (1) TN2010000136A1 (fr)
TW (1) TW200927142A (fr)
WO (1) WO2009048993A2 (fr)
ZA (1) ZA201001819B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115954A1 (fr) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb>
ES2526119T3 (es) 2008-08-18 2015-01-07 Novartis Ag Derivado de azetidina para el tratamiento de neuropatías periféricas
WO2010072703A1 (fr) 2008-12-22 2010-07-01 Novartis Ag Régime posologique d'un agoniste du récepteur s1p
PL2379067T3 (pl) * 2008-12-22 2016-02-29 Novartis Ag Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego
WO2011131370A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod granulé fondu
US20130102682A1 (en) * 2010-04-22 2013-04-25 Ratiopharm Gmbh Fingolimod in the form of a solid solution
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
US20150218090A1 (en) * 2011-10-21 2015-08-06 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (fr) 2011-12-22 2013-06-27 Synthon Bv Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (fr) * 2013-03-11 2014-09-18 Astron Research Limited Composition pharmaceutique stable de fingolimod
EP2996681B1 (fr) * 2013-05-13 2019-12-18 Synthon B.V. Composition pharmaceutique contenant du fingolimod
WO2015015254A1 (fr) 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Compositions pharmaceutiques à base de fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
EP3392244A1 (fr) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3129006B1 (fr) * 2014-04-10 2021-01-27 Novartis AG Formulation d'immunosuppresseur
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
WO2016026461A1 (fr) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Composition solide de fingolimod et préparation associée
WO2016042493A1 (fr) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
HK1246653A1 (zh) * 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
HK1245646A1 (zh) * 2015-04-28 2018-08-31 安斯泰来制药有限公司 口服给药用医药组合物
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
US20180280322A1 (en) * 2015-10-02 2018-10-04 Mylan Inc. Stable formulations of fingolimod
US10166221B2 (en) * 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (fr) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Formulations stables de fingolimod
WO2020006073A1 (fr) 2018-06-28 2020-01-02 Arx, Llc Procédé de distribution pour produire des constructions de film de dose unitaire soluble
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
EP3862318A4 (fr) 2018-10-05 2022-06-15 Fuji Chemical Industry Co., Ltd. Composition de particules de silice poreuse
KR102885760B1 (ko) * 2021-04-14 2025-11-13 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법
CN117120037A (zh) * 2021-04-14 2023-11-24 株式会社Lg化学 包含具有受控粒度的鞘氨醇-1-磷酸酯受体激动剂的药物组合物
WO2022220593A1 (fr) * 2021-04-14 2022-10-20 주식회사 엘지화학 Composition pharmacologique directement compressible comprenant un agoniste du récepteur de sphingosine-1-phosphate
WO2024126409A1 (fr) 2022-12-12 2024-06-20 Synthon B.V. Composition pharmaceutique contenant du siponimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (fr) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
ATE279185T1 (de) 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
DE69840169D1 (de) 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
CA2286315C (fr) 1997-04-04 2007-03-06 Yoshitomi Pharmaceutical Industries Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
NZ533997A (en) 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
AU2003264430B2 (en) 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
DK1602660T3 (da) 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
DE202004021680U1 (de) * 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
MXPA05014216A (es) 2003-06-24 2006-03-13 Univ Connecticut Metodos para inhibir permeabilidad vascular y apoptosis.
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
US20050090520A1 (en) * 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (fr) 2004-05-05 2005-12-01 Adler, Richard, S. Systemes et techniques de protection d'un bateau contre des attaques en surface ou sous l'eau
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006102611A2 (fr) 2005-03-24 2006-09-28 The Ohio State University Research Foundation Agents therapeutiques pour le traitement de la leucemie
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
SI3103448T1 (sl) * 2006-09-26 2019-11-29 Novartis Ag Farmacevtski sestavek, ki vsebuje modulator S1P

Also Published As

Publication number Publication date
HUE053835T2 (hu) 2021-07-28
CN101820916A (zh) 2010-09-01
US9399066B2 (en) 2016-07-26
ECSP10010169A (es) 2010-06-29
MY159358A (en) 2016-12-30
RU2010118457A (ru) 2011-11-20
BRPI0818161B8 (pt) 2021-05-25
EP2209493A2 (fr) 2010-07-28
ES2864671T3 (es) 2021-10-14
IL255737B (en) 2020-10-29
HK1213768A1 (en) 2016-07-15
ZA201001819B (en) 2010-12-29
SI2952177T1 (sl) 2021-07-30
US20170368001A1 (en) 2017-12-28
DK2952177T3 (da) 2021-04-26
TW200927142A (en) 2009-07-01
KR20100091179A (ko) 2010-08-18
PT2465492E (pt) 2015-10-15
PL2465492T3 (pl) 2015-11-30
RU2016138157A (ru) 2018-12-13
JOP20210187A1 (ar) 2021-07-08
HRP20150838T1 (hr) 2015-11-06
WO2009048993A2 (fr) 2009-04-16
SG10201800085XA (en) 2018-02-27
PE20090799A1 (es) 2009-07-20
PE20130309A1 (es) 2013-03-30
JP6034000B2 (ja) 2016-11-30
US20100267675A1 (en) 2010-10-21
CO6270342A2 (es) 2011-04-20
EP3120833A1 (fr) 2017-01-25
US20150165046A1 (en) 2015-06-18
KR101600098B1 (ko) 2016-03-04
EP3733161A1 (fr) 2020-11-04
EP2465492A1 (fr) 2012-06-20
KR20170021904A (ko) 2017-02-28
IL255737A (en) 2018-01-31
TN2010000136A1 (en) 2011-09-26
CA2699788A1 (fr) 2009-04-16
MX2010003925A (es) 2010-05-05
BRPI0818161B1 (pt) 2020-12-22
IL204514B (en) 2018-01-31
ES2545361T3 (es) 2015-09-10
MX337152B (es) 2016-02-15
JP2011500583A (ja) 2011-01-06
AU2008310846C1 (en) 2022-10-06
CL2008003003A1 (es) 2009-05-15
KR20160025633A (ko) 2016-03-08
US8673918B2 (en) 2014-03-18
JOP20080436B1 (ar) 2023-03-28
AU2008310846B2 (en) 2012-06-21
PL2952177T3 (pl) 2021-07-19
RU2016138157A3 (fr) 2020-02-10
AR068986A1 (es) 2009-12-23
EP2952177A1 (fr) 2015-12-09
AU2008310846A1 (en) 2009-04-16
EP3733162A1 (fr) 2020-11-04
HUE027696T2 (en) 2016-10-28
EP2653154A1 (fr) 2013-10-23
SI2465492T1 (sl) 2015-12-31
PT2952177T (pt) 2021-04-26
US20140142192A1 (en) 2014-05-22
IL277999A (en) 2020-11-30
JP2015091822A (ja) 2015-05-14
CA2925175A1 (fr) 2009-04-16
US20160296481A1 (en) 2016-10-13
EP2465492B1 (fr) 2015-07-01
EP2952177B1 (fr) 2021-01-20
NZ600355A (en) 2013-02-22
BRPI0818161A2 (pt) 2017-05-16
WO2009048993A3 (fr) 2010-05-06
KR101710845B1 (ko) 2017-02-27
CA2699788C (fr) 2016-06-14
SG187458A1 (en) 2013-02-28
US20170151195A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MX2010003925A (es) Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p).
BRPI0612926B8 (pt) compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto
EA200870079A1 (ru) Замещенные имидазолы и их применение в качестве пестицидов
ECSP088854A (es) Moduladores bencimidazolicos de vr1
MX2019012750A (es) Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
TN2014000243A1 (fr) Benzopyrannes nouveaux, compositions les contenant et leurs utilisations
DOP2010000229A (es) Compuestos que comprenden un grupo ciclobutoxi
SV2010003737A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
MA31311B1 (fr) Dérivés d&#39;indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
EA200901098A1 (ru) Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов
MA33131B1 (fr) Nouveaux derives de benzothiadiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA30778B1 (fr) Derives de sulfonamides servant d&#39;agonistes adrenergique et d&#39;antagonistes muscariniques
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112012027385A2 (pt) composição para o controle de doenças de plantas e uso da mesma
BRPI0900983A2 (pt) compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA32061B1 (fr) Triazolopyridazines en tant qu&#39;inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
MA38410A1 (fr) Composés d&#39;azétidinyloxyphénylpyrrolidine